Skip to main content

Prevalence and association of frailty with SARS-CoV-2 infection in older adults in Southern Switzerland—Findings from the Corona Immunitas Ticino Study



Frailty is an age-associated state of increased vulnerability to stressors that strongly predicts poor health outcomes. Epidemiological evidence on frailty is limited during the COVID-19 pandemic, and whether frailty is associated with the risk of infection is unknown.


We derived a robust Frailty Index (FI) to measure the prevalence of frailty and its risk factors in community-dwelling older adults in Southern Switzerland (Ticino), and we explored the association between frailty and serologically confirmed SARS-CoV-2 infection.


In September 2020, we recruited a random sample of community-dwelling older adults (65 +) in the Corona Immunitas Ticino prospective cohort study (CIT) and assessed a variety of lifestyle and health characteristics. We selected 30 health-related variables, computed the Rockwood FI, and applied standard thresholds for robust (FI < 0.1), pre-frail (0.1 ≤ FI < 0.21), and frail (FI ≥ 0.21).


Complete data for the FI was available for 660 older adults. The FI score ranged between zero (no frailty) and 0.59. The prevalence of frailty and pre-frailty were 10.3% and 48.2% respectively. The log-transformed FI score increased by age similarly in males and females, on average by 2.8% (p < 0.001) per one-year increase in age. Out of 481 participants with a valid serological test, 11.2% were seropositive to either anti-SARS-CoV-2 IgA or IgG. The frailty status and seropositivity were not statistically associated (p = 0.236).


Advanced age increases the risk of frailty. The risk of COVID-19 infection in older adults may not differ by frailty status.

Peer Review reports


The world’s population aged 65 years or older is expected to more than double from 0.7 billion in 2019 to 1.5 billion in 2050 [1]. Though global population ageing is a major societal achievement, it poses enormous public health challenges. Screening and monitoring age-related health conditions such as frailty is crucial [2].

Frailty is a geriatric condition characterized by increased vulnerability to endogenous and exogenous stressors, which is strongly associated with dependency and increased mortality [3, 4]. However, the construct validity of frailty is still debated, and consensus is lacking on how it should be assessed [2]. The Rockwood´s Frailty Index (FI) is a highly adaptive approach whereby frailty is conceived as an accumulation of health deficits that span a variety of health-related domains [5]. The FI approach has become increasingly popular because it is a better predictor of health-related adverse consequences than other frailty measurements [4, 6]. Moreover, the FI approach does not necessarily require a physical examination and it can be derived from pre-existing electronic health records or data from health surveys [4, 7, 8].

Previous studies showed that frailty might contribute to dysregulations of the immune system including low grade chronic inflammation, altered general and specialized immune response [9], which may contribute to the susceptibility to COVID-19 infection [10]. During the COVID-19 pandemic, most studies related to frailty were conducted in clinical settings typically using Clinical Frailty Scale [11], often administered by experienced health professionals [12]. Evidence suggests that frailty is a strong predictor of developing severe forms of COVID-19 and is associated with COVID related death in clinical settings [13,14,15]. However, evidence is limited on the prevalence of frailty in the general population during the COVID-19 pandemic, and whether frailty is associated with SARS-CoV-2 infection in community dwelling older adults.

We derived a robust FI combining a wide array of measures from an existing population-based study on the impact of the COVID-19 pandemic. We aimed to 1) calculate the prevalence of frailty in community-dwelling older adults in Southern Switzerland (Ticino); 2) explore the risk factors of frailty; and 3) explore the association between frailty and serologically confirmed COVID-19 infections.


Study design

Corona Immunitas Ticino (CIT) is a population-based prospective seroprevalence study that started in July 2020, after the first COVID-19 epidemic wave and lockdown in Southern Switzerland. The main aim of CIT was to assess the spread and impact of the COVID-19 pandemic. CIT is part of Corona Immunitas (CI), a nationwide research program led by the Swiss School of Public Health (SSPH +) [16]. Detailed information about the study design is reported elsewhere [16, 17].

Study setting and participants

CIT was conducted in Southern Switzerland—Canton Ticino, which borders Lombardy, Italy, the epicentre of the epidemic in Europe. We recruited participants using age- and sex- stratified random sampling based on regional registries of the Federal Office of Statistics. For this study on frailty, we considered 874 older adults aged 65 years and older, who agreed to participate in September and November 2020, provided informed consent and responded to the baseline questionnaire. Of these, we excluded 114 participants due to missing values for the computation of the FI (described below). This reduced the analytical sample size (n1) for the FI construction to 660. The included and excluded participants had similar age distributions. For the further assessment of the relationship between frailty and seroprevalence, we analysed data of the subsample of older adults who took part in the serosurvey and who had a valid serological test (n2 = 481).

Data collection

The Research Electronic Data Capture (REDCap) [18, 19], a secure, web-based platform hosted at the Università della Svizzera italiana (USI) was used for questionnaire development, data collection, storage, and management. Older participants were also offered the possibility to participate over the phone with a dedicated interviewer using computer-assisted telephone interviewing (CATI).

We asked participants to complete a baseline questionnaire following registration with the study. One week after the completion of the baseline assessment, we administered monthly and weekly questionnaires for repeated measures. We enquired about socio-demographic characteristics, physical and psychological health status, social relationships, and lifestyles of participants and their household environments.

To measure seropositivity to SARS-CoV-2, we invited participants to two rounds of blood testing. Professional nurses collected peripheral venous blood samples at a chosen healthcare facility or in their homes. The samples were analysed with the Luminex binding assay SenASTrIS (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological) to detect SARS-CoV-2 antibodies. Previous validations in population-based samples showed high sensitivity and specificity [20].

For the current paper, we used data from the baseline questionnaire, the third monthly questionnaire and the laboratory results from the serological test performed between November 2020 and January 2021 (before the introduction of vaccines).

Frailty Index Construction

We derived the Rockwood FI using the method described by Searle et al. [4]. We included 30 variables that covered seven domains including chronic diseases, basic activities of daily living, instrumental activities of daily livings, lifestyle, physical measurements, self-reported health status, and psychological symptoms (Supplementary Table 1). The rationale of the FI is that the deficits/impairments should be related to ill-health status, should cover a variety of health domains, should progressively increase with age, and should not saturate at relatively younger age. The six deficits related to psychological symptoms and signs were selected from the third monthly questionnaire and the remaining 24 deficits were extracted from the baseline questionnaire. The FI is calculated as the ratio of the sum of deficits reported to the total number of deficits considered, and we applied a previously validated cut-off (i.e., 0.21) for frailty caseness [21]. We considered 0.1 ≤ FI < 0.21 as pre-frail, FI < 0.1 as robust [21]. For example, if a participant reported 6 out of 30 deficits considered, his/her FI would be 0.2, and would be classified as pre-frail. Before computing the FI, we recoded binary variables according to their possible answers as either ‘0’ or ‘1’, with ‘1’ representing the presence of a health deficit. For ordinal variables, we used a Likert-like scale. We assigned values of ‘0’, ‘0.5’, ‘1’ to variables with 3 possible answers; ‘0’, ‘0.33’, ‘0.67’, ‘1’ to variables with 4 possible answers; and ‘0’, ‘0.25’, ‘0.5’, ‘0.75’, ‘1’ to variables with 5 possible answers. For the continuous variables, such as BMI (Body Mass Index), we used universally agreed cut-offs [22] to categorize the responses (see Supplementary Table 1), then we assigned values accordingly using the abovementioned method.


For the analysis of potential risk and protective factors of frailty, we used sociodemographic and lifestyle measures collected at baseline including age (modelled as continuous and categorical variable for analytic purposes, namely 65–69 years old, 70–74 years old, 75–79 years old and 80 years old and plus); sex (male/female), income satisfaction (i.e. ‘not enough’, ‘enough’ and ‘more than enough’), education (‘none’, ‘compulsory education’, ‘higher secondary education’, and ‘university’) and smoking (‘non-smoker’, ‘past smoker’ and ‘current smoker’).

To explore whether there is any relationship between frailty and serologically confirmed SARS-CoV-2 infection, we included in our models the abovementioned sociodemographic factors, multimorbidity and frailty status (robust, pre-frail, frail). The multimorbidity was operationalized as a binary variable (yes/no). Participants who reported at least two chronic conditions were considered having multimorbidity: cardiovascular diseases (e.g., angina pectoris, peripheral vascular diseases, intermittent claudication, heart attack, stroke or heart failure), chronic respiratory conditions (chronic obstructive pulmonary disease, chronic bronchitis, emphysema or asthma), allergy (pollen allergy or hay fever), immune disorders, hypertension, diabetes mellitus, cancer or other conditions.

Statistical analysis

We used complete case analysis in our study because those participants with missing values on the items used to construct the FI were not significantly different from those with no missing values across socio-demographic characteristics. We first describe the socio-demographic characteristics of the sample. Means and standard deviation (SD) were used for normally distributed data, median and interquartile range (IQR) for skewed data, and Spearman correlations and Wilcoxon rank sum tests to compare groups.

We used Poisson regression to estimate the prevalence of frailty by sex and age group. We used log-transformed linear regressions to explore the association between age and FI. In addition, we used univariate and multivariable multinomial logistic regressions to assess associations between age group, sex, income satisfaction, education level and smoking status and frailty status.

Potential risk factors for SARS-CoV-2 seropositivity including age group, sex, smoking status, multimorbidity and frailty status, were tested separately using logistic regressions. A p value less than 0.05 was considered statistically significant. We performed all analyses using Stata Version 17.0 [23].

Sensitivity analysis

We conducted two sets of sensitivity analysis. Firstly, we used two-sample Kolmogorov–Smirnov test and the Mann–Whitney U test to compare the distribution of FI and the mean score of FI between the analytical sample who participated in the serological blood sampling and the sample who did not. We assumed that frail older people might be less likely to participate in the serological blood sampling which may contribute to dilute the results of the potential relationship between frailty and COVID-19 infection.

Secondly, we explored whether there is any potential relationship between sub-components of frailty and COVID-19 seropositivity using logistic regression. The seven subcomponents of the FI and the sum of all frailty components were included individually to the model as independent variables. The chronic diseases component’s score ranged from zero to eight, the one about basic activities of daily livings ranged from zero to five, instrumental activities of daily livings from zero to eight, and psychological symptoms and signs ranged from zero to six. The other three components (self-reported health, physical measurement, and lifestyle) all ranged from zero to one. The overall sum of the frailty items ranged from zero to 30.


Out of 874 respondents aged 65 years and over, complete data for the FI calculation was available for 660 participants (75.4%). The mean age of the study sample was 73 years, 57% were female, and 77% completed at least higher secondary education. Nearly 40% were either current or past smokers (Table 1). Overall, we identified 68 frail, 318 pre-frail, and 274 robust older adults.

Table 1 Sociodemographic of the study sample stratified by frailty level

Distribution and prevalence of frailty

The distribution of frailty was right skewed (Fig. 1). The FI score ranged from zero to 0.595 with a median of 0.111 (IQR = 0.085), and a mean of 0.123 (SD = 0.079). Table 2 shows the prevalence of frailty stratified by age groups. The prevalence of frailty increased with age (p = 0.005) but was similar for men and women at approximately 10%.

Fig. 1
figure 1

Histogram and density plot of Frailty Index

Table 2 Frailty Index score and frailty prevalence by age group

Participants with higher income satisfaction had a higher median FI score compared to those who reported lower income (Median = 0.103, IQR = 0.082). Median FI scores were also inversely associated with higher education level (p < 0.05). Those who did not complete compulsory education had a median FI score of 0.136 (IQR = 0.054), and people who received university education had a lower median score (i.e., were less frail) 0.099 (IQR = 0.080). We found no difference in FI scores by sex (p = 0.275) or between smokers and non-smokers (p = 0.612). In Fig. 2, the log-transformed FI score increased with age similarly in males and females, on average by 2.8% (SE = 0.004, p < 0.001) per one-year increase in age.

Fig. 2
figure 2

Relationship between age and log-transformed Frailty Index by sex

In multinomial mutually adjusted models, pre-frailty and frailty were respectively 1.28 and 1.90 times more likely by every 5-year age increments (p < 0.05), and higher income satisfaction was related to lower risk of frailty (p < 0.05) but not with pre-frailty (Table 3).

Table 3 Risk factors for frailty in multinomial logistic regression

Frailty and SARS-CoV-2 infection

To test whether frailty was associated with SARS-CoV-2 infection, we further excluded 179 participants who did not perform or lacked a valid serological test result, resulting in sub-sample of 481 participants. We found that 54 participants (11.2%) had developed antibodies against SARS-CoV-2. The proportion of seropositivity increased with frailty status. In the frail group, around 17% had positive serological results compared to 11% in the pre-frail group and 10% in the robust group. The frequencies and proportions of serological results of anti-SARS-CoV-2 antibodies stratified by frailty status are presented in Table 4.

Table 4 Serological results of anti-SARS-CoV-2 antibodies stratified by frailty status

The associations between potential risk factors for COVID-19 infection, including age, sex, smoking status, multimorbidity, self-reported health status, and frailty status were not statistically significant. Odds ratios (ORs) for these null associations with 95% robust CIs are presented in Supplementary Table 2.

Sensitivity analysis

From the results of two-sample Kolmogorov–Smirnov test (p = 0.202), we could not reject the null hypothesis that the distributions of FI were the same in those who participated in serological blood sampling and those did not. Moreover, Mann–Whitney U test showed that the mean of FI was not statistically significantly different between these two groups (z = 1.883, p = 0.060). In the second set of sensitivity analysis, neither of the seven sub-components of FI nor the overall sum score of frailty item were associated with COVID-19 infection (Supplementary Table 3).


We made use of a large array of measures to construct a 30-item FI in a random and fairly representative sample of older adults participating in an ongoing population-based cohort study during the COVID-19 pandemic. The prevalence of frailty in Southern Switzerland was 10.3% (CI: 8.12, 13.07), and almost half of the study participants were identified as pre-frail. Advanced age and lower income satisfaction were both positively associated with frailty. Neither frailty nor its sub-components was associated with serologically confirmed COVID-19 infection.

Our results on the occurrence of pre-frailty at around 48% are consistent with recent figures from a large meta-analysis that included studies conducted with people aged 50 years and over in 62 countries that found a pre-frailty prevalence of 49% [24]. Conversely, the prevalence of frailty was 24% in the same meta-analysis [24], which is more than twice that found in our study (10%). Moreover, the mean FI score of our sample (0.12) was lower than the mean FI score in Switzerland (0.19) reported in the SHARE study, and in other European countries [25,26,27]. We collected data during the COVID-19 pandemic, and its associated restrictions may have limited the participation of less healthy individuals, but self-selection of frail individuals in other studies may not be excluded given the different sampling and recruitment procedures between our study and previous studies.

Similar to other studies, the distribution of frailty was right skewed and upper limit was less than 0.7 [4, 26, 28]. It is commonly believed that older women tend to be frailer than men [4, 28,29,30], however we did not find significant differences by sex. Frailty level increased with age. The growth rate of the log-transformed FI per one year increase in age was 2.8% in our study, which is in line with the 3.5% found in a large Dutch study (LASA) [28]. The frequency of frailty increased with age but slightly decreased in the oldest old. Prevalence bias may not be excluded because frailty may be associated with poorer health and death competing risks in later life. Moreover, in our study the association between frailty and age increased more steeply in women compared to men in contrast to that found for Swiss older adults using data from SHARE [25].

Evidence suggests that older age, low income and multimorbidity may increase the risk of COVID-19 infection, while current smoking may lower it [31,32,33]. Evidence is inconsistent on the association between frailty and risk of COVID-19 infection. For example, one study showed that frailty was significantly associated with incident COVID-infection (adjusted HR = 7.01, 95% CI = 2.69–18.25) [10]. Consistent with what we observed, frailty was not related to higher risk of COVID-19 infection in a study based on the 11-item Edmonton Frailty Scale [34]. Similarly, a prospective analysis of UK Biobank data did not find associations between frailty (diagnosed using Fried frailty criteria) and multimorbidity with positive PCR test for COVID-19 [35]. Comparisons with previous studies are not straightforward because of the settings, the frailty measurements used, and their construct validity are markedly heterogeneous across studies. Moreover, during the COVID-19 pandemic older people especially those frail ones and those with multimorbidities were recommended to strictly comply with stay-at-home measures. Adherence to the public health measures was high among older population in Switzerland, and higher in those with pre-existing health conditions [36]. Higher adherence to preventive measures likely contributed to reducing contact between infected and susceptible individuals amongst frail and/or multimorbid older adults, counterbalancing the higher duration of infectiousness and probability of infection on contact in this group. Mechanistic evidence suggests that the latter two are higher in frail compared to robust older adults, irrespective of their age [9]. Further large-scale studies using the Rockwood FI approach to assess whether frailty predisposes older adults to COVID-19 infection mitigating the effect of preventive measures are warranted.


Our study has several limitations. Firstly, issues of directionality cannot be addressed in our analysis due to the cross-sectional design, which is, however, robust for the descriptive findings, including estimation of the prevalence of frailty. Moreover, as not all measures were repeated over time, we were unable to explore changes in frailty status through the pandemic waves. We know that frailty is a dynamic health condition [37], and it would be relevant to explore the transition and evolution of frailty status in the long term. Furthermore, although we implemented several measures to facilitate older adults' participation in the study (e.g., CATI and at-home blood sampling), the constraints imposed by the pandemic may have contributed to participation bias favouring healthier individuals. This may have led to an underestimation of the true prevalence of frailty. All the variables used to derive the FI were self-reported, which may have contributed to measurement error and recall bias. Whether this caused an under- or over-estimation of the true prevalence of frailty is unclear. Our results should be generalized with caution to similar populations. Finally, we cannot exclude that we lacked sufficient statistical power to detect a true effect of frailty on COVID-19 infection because of the relatively low seroprevalence in our sample.


Our study provides novel prevalence estimates of frailty based on the operationalization of the FI during the COVID-19 pandemic in Southern Switzerland. Epidemiological evidence on frailty is patchy or outdated in both Western and non-Western countries, due to inherent difficulties in recruiting and assessing frailty in representative samples of older adults.

The FI approach used in this study has several advantages over the traditional Fried frailty phenotype approach [38]. For instance, the phenotype approach is resource intense because it requires in-person interviews and assessments, including hand grip strength with a dynamometer [39]. In comparison, the FI approach relies on indirect indicators of physical fitness inferred from a variety of domains that do not necessarily require a physical examination. This was a main advantage given the physical distancing and hygiene measures and restrictions enforced during the COVID-19 pandemic. An additional advantage of the FI is its multidimensional approach that extends to mental, psychological, and cognitive health [4], all of which were largely impacted during the pandemic. We were able to include 30 health-related measures to construct the FI, a number widely considered sufficient to provide robust frailty estimates and FI scores [4]. It is worth mentioning that the alternative way to treat the ordinal variables is grouping the answers and converting them into dichotomous variables. However, previous research shows that as long as the number of deficits included is sufficient (at least 30), both scoring methods provide nearly identical results in terms of mean FI scores and its ability to predict mortality [40]. The internal validity of our study supports inferential reasoning that may suggest that potentially up to half of the population 65 + of Southern Switzerland could benefit from interventions aimed at preventing and reversing frailty, including dietary supplements or increased intake of vitamin D and proteins [41,42,43].


In conclusion, the prevalence of frailty and pre-frailty was high among older adults in Southern Switzerland after the first lockdown and during the COVID-19 pandemic. Our study is exemplar of turning a dreadful public health emergency into an opportunity to collect and use epidemiological data to fill evidence gaps. Prospective data are warranted to monitor changes in frailty occurrence, to study its impact on individuals and society, and to gauge mid- and long-term consequences of the COVID-19 pandemic on frail and pre-frail older adults. However, our findings highlight prevention opportunities of public health significance because of the steady expansion of the older segment of the population in the region and globally.

Availability of data and materials

All data sharing and collaboration requests should be directed to the corresponding author MJ ( and the senior author EA (



Frailty Index


Corona Immunitas Ticino


Corona Immunitas

SSPH + :

Swiss School of Public Health


Research Electronic Data Capture


Università della Svizzera italiana


Computer Assisted Telephone Interviewing


Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological


Immunoglobulin G


Immunoglobulin A


Body Mass Index


  1. United Nations, Department of Economic and Social Affairs, Population Division. World population ageing, 2019 highlights. 2020. Accessed 6 June 2022.

  2. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394:1365–75.

    Article  Google Scholar 

  3. Xue Q-L. The Frailty Syndrome: Definition and Natural History. Clin Geriatr Med. 2011;27:1–15.

    Article  CAS  Google Scholar 

  4. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24.

    Article  Google Scholar 

  5. Rockwood K, Mitnitski A. Frailty in Relation to the Accumulation of Deficits. J Gerontol Series A. 2007;62:722–7.

    Article  Google Scholar 

  6. Blodgett J, Theou O, Kirkland S, Andreou P, Rockwood K. Frailty in NHANES: Comparing the frailty index and phenotype. Arch Gerontol Geriatr. 2015;60:464–70.

    Article  Google Scholar 

  7. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45:353–60.

    Article  Google Scholar 

  8. Orfila F, Carrasco-Ribelles LA, Abellana R, Roso-Llorach A, Cegri F, Reyes C, et al. Validation of an electronic frailty index with electronic health records: eFRAGICAP index. BMC Geriatr. 2022;22:404.

    Article  Google Scholar 

  9. Yao X, Li H, Leng SX. Inflammation and Immune System Alterations in Frailty. Clin Geriatr Med. 2011;27:79–87.

    Article  Google Scholar 

  10. Lengelé L, Locquet M, Moutschen M, Beaudart C, Kaux J-F, Gillain S, et al. Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. Aging Clin Exp Res. 2022;34:223–34.

    Article  Google Scholar 

  11. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.

    Article  Google Scholar 

  12. Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. Can Geriatr J. 2020;23:210–5.

    Article  Google Scholar 

  13. Sablerolles RSG, Lafeber M, van Kempen JAL, van de Loo BPA, Boersma E, Rietdijk WJR, et al. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study. Lancet Healthy Longevity. 2021;2:e163–70.

    Article  Google Scholar 

  14. Bielza R, Sanz J, Zambrana F, Arias E, Malmierca E, Portillo L, et al. Clinical Characteristics, Frailty, and Mortality of Residents With COVID-19 in Nursing Homes of a Region of Madrid. J Am Med Dir Assoc. 2021;22:245-252.e2.

    Article  Google Scholar 

  15. Pranata R, Henrina J, Lim MA, Lawrensia S, Yonas E, Vania R, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021;93:104324.

    Article  CAS  Google Scholar 

  16. West EA, Anker D, Amati R, Richard A, Wisniak A, Butty A, et al. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health. 2020;65:1529–48.

    Article  Google Scholar 

  17. Speierer A, Chocano-Bedoya PO, Anker D, Schmid A, Keidel D, Vermes T, et al. The Corona Immunitas Digital Follow-Up eCohort to Monitor Impacts of the SARS-CoV-2 Pandemic in Switzerland: Study Protocol and First Results. Int J Public Health. 2022;67:1604506.

  18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.

    Article  Google Scholar 

  19. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.

    Article  Google Scholar 

  20. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2021;95:e01828-20.

    Article  CAS  Google Scholar 

  21. Hoover M, Rotermann M, Sanmartin C, Bernier J. Validation of an index to estimate the prevalence of frailty among community-dwelling seniors. Health Rep. 2013;24:10–7.

    Google Scholar 

  22. WHO Consultation on Obesity (1999: Geneva, Switzerland) & World Health Organization. (2000). Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organization Technical Report Series No. 894; Geneva. Accessed 16 Sep 2022.

  23. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.

    Google Scholar 

  24. O’Caoimh R, Sezgin D, O’Donovan MR, Molloy DW, Clegg A, Rockwood K, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50:96–104.

    Article  Google Scholar 

  25. Harttgen K, Kowal P, Strulik H, Chatterji S, Vollmer S. Patterns of Frailty in Older Adults: Comparing Results from Higher and Lower Income Countries Using the Survey of Health, Ageing and Retirement in Europe (SHARE) and the Study on Global AGEing and Adult Health (SAGE). PLoS One. 2013;8:e75847.

    Article  CAS  Google Scholar 

  26. Jiang M, Foebel AD, Kuja-Halkola R, Karlsson I, Pedersen NL, Hägg S, et al. Frailty index as a predictor of all-cause and cause-specific mortality in a Swedish population-based cohort. Aging (Albany NY). 2017;9:2629–46.

    Article  Google Scholar 

  27. Williams DM, Jylhävä J, Pedersen NL, Hägg S. A Frailty Index for UK Biobank Participants. J Gerontol A Biol Sci Med Sci. 2019;74:582–7.

    Article  Google Scholar 

  28. Hoogendijk EO, Theou O, Rockwood K, Onwuteaka-Philipsen BD, Deeg DJH, Huisman M. Development and validation of a frailty index in the Longitudinal Aging Study Amsterdam. Aging Clin Exp Res. 2017;29:927–33.

    Article  Google Scholar 

  29. Kane AE, Howlett SE. Sex differences in frailty: Comparisons between humans and preclinical models. Mech Ageing Dev. 2021;198: 111546.

    Article  CAS  Google Scholar 

  30. Corbi G, Cacciatore F, Komici K, Rengo G, Vitale DF, Furgi G, et al. Inter-relationships between Gender, Frailty and 10-Year Survival in Older Italian Adults: an observational longitudinal study. Sci Rep. 2019;9:18416.

    Article  CAS  Google Scholar 

  31. Chudasama YV, Zaccardi F, Gillies CL, Razieh C, Yates T, Kloecker DE, et al. Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the UK. BMC Infect Dis. 2021;21:908.

    Article  CAS  Google Scholar 

  32. D’ascanio M, Innammorato M, Pasquariello L, Pizzirusso D, Guerrieri G, Castelli S, et al. Age is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes. BMC Geriatr. 2021;21:63.

    Article  Google Scholar 

  33. Paleiron N, Mayet A, Marbac V, Perisse A, Barazzutti H, Brocq F-X, et al. Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study. Nicotine Tob Res. 2021;23:1398–404.

    Article  CAS  Google Scholar 

  34. Del Brutto OH, Costa AF, Recalde BY, Mera RM. Frailty and SARS-CoV-2 infection. A population-based study in a highly endemic village. J Neurol Sci. 2020;418:117136.

    Article  Google Scholar 

  35. Woolford SJ, D’Angelo S, Curtis EM, Parsons CM, Ward KA, Dennison EM, et al. COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants. Aging Clin Exp Res. 2020;32:1897–905.

    Article  CAS  Google Scholar 

  36. Bearth A, Luchsinger L, Siegrist M. Reactions of older Swiss adults to the COVID-19 pandemic: a longitudinal survey on the acceptance of and adherence to public health measures. Soc Sci Med. 2021;280:114039.

    Article  Google Scholar 

  37. Kojima G, Taniguchi Y, Iliffe S, Jivraj S, Walters K. Transitions between frailty states among community-dwelling older people: a systematic review and meta-analysis. Ageing Res Rev. 2019;50:81–8.

    Article  Google Scholar 

  38. Cesari M, Gambassi G, Abellan Van Kan G, Vellas B. The frailty phenotype and the frailty index: different instruments for different purposes. Age Ageing. 2014;43:10–2.

    Article  Google Scholar 

  39. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in Older Adults: Evidence for a Phenotype. J Gerontol Series A. 2001;56:M146–57.

    Article  CAS  Google Scholar 

  40. Peña FG, Theou O, Wallace L, Brothers TD, Gill TM, Gahbauer EA, et al. Comparison of alternate scoring of variables on the performance of the frailty index. BMC Geriatr. 2014;14:25.

    Article  Google Scholar 

  41. Bruyère O, Cavalier E, Buckinx F, Reginster J-Y. Relevance of vitamin D in the pathogenesis and therapy of frailty. Curr Opin Clin Nutr Metab Care. 2017;20:26–9.

    Article  Google Scholar 

  42. Zhou J, Huang P, Liu P, Hao Q, Chen S, Dong B, et al. Association of vitamin D deficiency and frailty: a systematic review and meta-analysis. Maturitas. 2016;94:70–6.

    Article  CAS  Google Scholar 

  43. Beasley JM, LaCroix AZ, Neuhouser ML, Huang Y, Tinker L, Woods N, et al. Protein Intake and Incident Frailty in the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2010;58:1063–71.

    Article  Google Scholar 

  44. Symposia - Conferences - Oral Communications. J Frailty Aging. 2022;11:1–45. Accessed 14 Sep 2022.

Download references


This work was presented in part at the International Conference on Frailty and Sarcopenia Research conference in April 2022, in the form of online oral presentation titled “Prevalence of frailty in older adults during the COVID-19 pandemic in Southern Switzerland: the Corona Immumitas Ticino cohort study” [44].

We are grateful for the Corona Immunitas Ticino Working Group: Emiliano Albanese, Rebecca Amati, Antonio Amendola, Anna Maria Annoni, Granit Baqaj, Kleona Bezani, Peter Buttaroni, Anne-Linda Camerini, Anna Paola Caminada, Elia Cattani, Alessandro Ceschi, Laurie Corna, Cristina Corti Fragoso, Luca Crivelli, Diana Sofia Da Costa Santos, Giorgio Dal Bò, Gladys Delai Venturelli, Daniela Dordoni, Marta Fadda, Luca Faillace, Ilaria Falvo, Paolo Ferrari, Maddalena Fiordelli, Carolina Foglia, Giovanni Franscella, Sara Gamberoni, Roberta Gandolfi, Rosita Ghidossi, Daniele Giottonini, Paola Guglielmetti, Sandra Jovic, Franco Keller, Sara Levati, Isabella Martinelli, Federico Mele, Rosalba Morese, Anna Papis, Giovanni Piumatti, Greta Rizzi, Serena Sabatini, Federica Sallusto, Tatiana Terrot, Mauro Tonolla.

We are grateful to the funding bodies of the CIT study, all the working group members and to the study participants, without whom this study would not have been possible. We are thankful to the reviewers and Prof. Matteo Cesari for their insightful comments and suggestions. Dr. Miao Jiang is funded in part by the Global PhD Fellowship Program in Public Health Sciences from the Swiss School of Public Health funded by Marie Skłodowska-Curie Actions (Horizon 2020—COFUND).


Corona Immunitas Ticino is part of the Corona Immunitas national research program, coordinated and funded by the Swiss School of Public Health (SSPH +) through fundraising from private and public sources (e.g., Swiss Federal Office of Public Health). Additional funding in Ticino was provided by the Ceresio Foundation. Miao Jiang has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 801076, through the SSPH + Global PhD Fellowship Programme in Public Health Sciences (GlobalP3HS) of the Swiss School of Public Health. The funding bodies had no role in the design and conduction of the study, in data collection, data management, data analysis, interpretation of findings, and writing of the manuscript.

Author information

Authors and Affiliations



All authors worked collectively to develop the protocols and methods described in this paper. MJ and EA conceived and designed the present study design. MJ constructed and computed the Frailty Index and analysed the data. MJ wrote the first draft of the manuscript under the supervision of EA. GP provided statistical supports. L Corna, RA, GP and EA provided critical revision of the manuscript. RA, GF, GP, L Corna, L Crivelli and EA contributed to the acquisition of the data. All authors contributed to data interpretation and manuscript revision and approved the submitted paper.

Corresponding author

Correspondence to Miao Jiang.

Ethics declarations

Ethics approval and consent to participate

The Corona Immunitas Ticino study was approved by the Ethics Committees of Canton Ticino (BASEC 2020–01514). This study was conducted in accordance with the Declaration of Helsinki and all participants provided informed consent before joining the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Table 1.

Thirty health deficits and their scoring used to derive the Frailty Index. Supplementary Table 2. Univariate logistic regression model for potential risk factors of SARS-CoV-2 infection. Supplementary Table 3. Univariate logistic regression model to assess the association between sub-components of Frailty Index and SARS-CoV-2 infection—a sensitivity analysis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, M., Corna, L., Amati, R. et al. Prevalence and association of frailty with SARS-CoV-2 infection in older adults in Southern Switzerland—Findings from the Corona Immunitas Ticino Study. BMC Geriatr 23, 18 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: